Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC
Status:
Recruiting
Trial end date:
2023-10-17
Target enrollment:
Participant gender:
Summary
A Phase 4 study to assess Overall and Intracranial Response Rate of single-agent lorlatinib
in participants with advanced ALK-positive NSCLC whose disease has progressed on alectinib or
ceritinib as the first ALK tyrosine kinase inhibitor (TKI)therapy.